Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NA-931 in Overweight/Obese and T2DM Participants
NCT06615700Phase 1Completed
- Sponsor
- Biomed Industries
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Overweight, obesity and type 2 diabetes mellitus (T2DM) comparing NA-931 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 28 days. Started May 2024; status: completed.
02
Drugs
NA-931
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06615700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615700.